UPADACITINIB
upadacitinib 15 mg modified release tablet, 28
UPADACITINIB (11989B)
11989B
Manner of administration:Oral
Restriction
Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)
Restriction
Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break
in biological medicine of less than 24 months)
Restriction
Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological
medicine of more than 24 months)
Restriction
Indication: Severe active rheumatoid arthritis
Treatment phase: Balance of supply - Initial 1 (new patient) or Initial 2 (change or recommencement
of treatment after a break in biological medicine of less than 24 months) or Initial
3 (recommencement of treatment after a break in biological medicine of more than 24
months)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 3 | DPMQ: $1,212.73 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Rinvoq | |||||